On July 10, 2025, Aqtual, a Hayward, California-based precision medicine company, announced the closing of its $31 million Series B financing round. Investors in the oversubscribed round included Bold Capital, the Bold Longevity Growth Fund, Genoa Ventures, Manta Ray Ventures, Yu Galaxy, and others. Wilson Sonsini Goodrich & Rosati advised Aqtual on the transaction.

Aqtual is pioneering a novel cell-free DNA (cfDNA) platform designed to advance chronic disease management and oncology care. The platform leverages active chromatin to evaluate protein regulation, epigenetics, and transcriptomics using only cfDNA fragments found in blood—offering real-time insights into disease and treatment response while addressing the limitations of earlier cfDNA technologies.

Aqtual’s proprietary approach enables high-fidelity, tissue-specific quantification of gene regulation by integrating profiling of the disease itself, the surrounding microenvironment, and the systemic immune response—all from a simple blood draw.

The Wilson Sonsini team that advised Aqtual on the transaction includes:

Corporate
Priyanka Nawathe
Taylor Miller
Jennifer Fang

Patents
Adam Cole

Technology Transactions
Norm Hovijitra

For more information, please see Aqtual’s press release here.